BIIB Stock: Biogen Inc. Stock Price, Analysis & Insights
Get live biib stock price $154.27, comprehensive Biogen Inc. stock analysis, charts, news, and expert forecast. Real-time biib stock data and investment insights.
Loading chart...
Company Overview
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB135, BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, Lecanemab, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and BIIB131 to treat acute neurology; BIIB074 for neuropathic pain; and BYOOVIZ, BIIB800, and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Company Information
- CEO
- Christopher A. Viehbacher
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Employees
- 7605
Contact Information
- Website
- https://www.biogen.com
- Address
- 225 Binney Street
- Country
- US
Investment Analysis & Business Insights
Investment Highlights
✓ Strong presence in the Healthcare sector with established market position
✓ Valuation metrics suggest potential value opportunity (P/E: 14.1)
✓ Lower volatility stock (Beta: 0.13) may provide portfolio stability
Business Model & Strategy
Biogen Inc. operates in the Drug Manufacturers - General industry, focusing on medical services, pharmaceutical development, and healthcare delivery. Under the leadership of CEO Christopher A. Viehbacher, the company navigates Healthcare sector dynamics while pursuing growth opportunities. The Drug Manufacturers - General model requires regulatory compliance, research investment, and patient outcomes to maintain competitiveness and drive shareholder value.
Market Position & Competitive Landscape
Biogen Inc. competes in the Drug Manufacturers - General within the broader Healthcare. With 22.6 billion in market capitalization, the company is positioned as a established player in its sector. The Healthcare is characterized by demographic shifts, regulatory changes, and medical breakthroughs. As a publicly traded company on the NASDAQ Global Select, Biogen Inc. provides investors with liquidity and transparency while subject to regulatory oversight. Investors evaluating Biogen Inc. should consider industry-specific trends, competitive positioning, and Healthcare sector fundamentals.
Important Investment Considerations
- ⚠All investments carry risk, including potential loss of principal for Biogen Inc. shareholders
- ⚠Market volatility can significantly impact stock price, especially for mid-cap stocks
- ⚠Sector-specific risks in Healthcare may affect company performance
- ⚠Past performance does not guarantee future results for Biogen Inc.
- ⚠Investors should consider how Biogen Inc. fits within their overall portfolio allocation
- ⚠Valuation metrics suggest potential, but require fundamental analysis
Market Cap
22.63B
P/E Ratio
14.06
Beta
0.13
Investment Analysis & Insights
Key Investment Highlights
- Market Position: Healthcare leader with 22.63B market capitalization
- Trading Volume: 2.24M shares traded today
- Price Range: 52-week range of $110.04 - $179.20
- Exchange: Listed on NASDAQ Global Select
Financial Metrics
Market Analysis for Biogen Inc.
Biogen Inc. (BIIB) operates in the Drug Manufacturers - General industry within the Healthcare sector. With a current market capitalization of 22.63B, the company represents a significant player in its market. The stock is currently trading at $154.27 with a positivedaily change of 3.11%.
The company's 7605 employee base and presence on the NASDAQ Global Selectexchange position it as a Healthcare sector leader. Investors should consider the stock's P/E ratio of 14.06, beta of 0.13, and 52-week price range from $110.04 to $179.20when evaluating investment opportunities.
Why Invest in Biogen Inc.?
Strengths
- • Established market presence in Healthcare
- • Strong financial metrics and market position
- • Listed on major exchange (NASDAQ Global Select)
- • Experienced leadership under Christopher A. Viehbacher
Investment Considerations
- • Monitor sector-specific market trends
- • Track quarterly earnings performance
- • Consider market volatility and beta
- • Evaluate long-term growth potential
Related Healthcare Stocks
About Healthcare Sector
The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.